Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.62 +0.8%	$14.61	$9.57 ▼ $30.41	$2.16B	0.96	1.54 million shs	1.20 million shs
BHC Bausch Health Cos	$6.19 +8.1%	$4.94	$3.96 ▼ $9.85	$2.29B	0.28	2.63 million shs	4.64 million shs
NAMS NewAmsterdam Pharma	$18.20 -1.6%	$18.45	$14.06 ▼ $27.29	$2.04B	-0.03	694,190 shs	633,421 shs
SANA Sana Biotechnology	$2.76 -1.8%	$2.06	$1.26 ▼ $7.40	$622.32M	1.78	3.57 million shs	3.52 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+0.77%	-6.69%	-0.76%	+3.38%	-33.74%
BHC Bausch Health Cos	+8.04%	+16.30%	+33.47%	-12.71%	-4.36%
NAMS NewAmsterdam Pharma	-1.57%	-11.22%	-4.36%	-24.39%	+6.37%
SANA Sana Biotechnology	-1.78%	+2.22%	+64.29%	+22.12%	-51.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5206 of 5 stars	3.4	1.0	3.4	2.3	2.5	0.0
BHC Bausch Health Cos	3.7318 of 5 stars	1.9	2.0	4.0	4.0	3.3	0.6
NAMS NewAmsterdam Pharma	3.009 of 5 stars	3.5	2.0	0.0	2.6	5.0	0.0
SANA Sana Biotechnology	1.6779 of 5 stars	3.4	0.0	0.0	0.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	179.86% Upside
BHC Bausch Health Cos	1.86	Reduce	$7.42	19.76% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	135.65% Upside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	291.30% Upside

Current Analyst Ratings Breakdown

Latest SANA, NAMS, BHC, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/2/2025	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$8.50 ➝ $10.00
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
4/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	607.64	N/A	N/A	$1.54 per share	10.14
BHC Bausch Health Cos	$9.63B	0.24	$7.74 per share	0.80	($0.89) per share	-6.96
NAMS NewAmsterdam Pharma	$45.56M	44.85	N/A	N/A	$8.20 per share	2.22
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	18.37	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.33	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)

Latest SANA, NAMS, BHC, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
BHC Bausch Health Cos	N/A	1.35	0.97
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
SANA Sana Biotechnology	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BHC Bausch Health Cos	78.65%
NAMS NewAmsterdam Pharma	89.89%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BHC Bausch Health Cos	8.05%
NAMS NewAmsterdam Pharma	20.84%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
SANA Sana Biotechnology	380	225.48 million	157.61 million	Optionable

SANA, NAMS, BHC, and ARWR Headlines

Recent News About These Companies

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 7.3% - Still a Buy?

June 17 at 1:35 PM | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 7.2% - Here's Why

June 11, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 8.3% - What's Next?

June 10, 2025 | marketbeat.com

Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

June 9, 2025 | globenewswire.com

Two Sigma Investments LP Grows Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 8, 2025 | marketbeat.com

Biggest Stocks in NASDAQ Featuring Sana Biotechnology and Kalkine

June 7, 2025 | kalkinemedia.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Stock Position Raised by Two Sigma Advisers LP

June 6, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Millennium Management LLC

June 5, 2025 | marketbeat.com

Sana Biotechnology (NASDAQ:SANA) Trading Up 10.9% - Time to Buy?

June 4, 2025 | marketbeat.com

Bank of America Corp DE Increases Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

June 4, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Sold by Voloridge Investment Management LLC

May 31, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

May 29, 2025 | marketbeat.com

Jane Street Group LLC Boosts Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

May 29, 2025 | marketbeat.com

Sana Biotechnology to Present at June 2025 Investor Conferences

May 28, 2025 | globenewswire.com

Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025

May 20, 2025 | accessnewswire.com

SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

May 20, 2025 | globenewswire.com

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology

May 20, 2025 | tmcnet.com

Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky

May 20, 2025 | accessnewswire.com

SANA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA

May 20, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA

May 20, 2025 | prnewswire.com

Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025

May 20, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA, NAMS, BHC, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.62 +0.12 (+0.77%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$15.59 -0.03 (-0.20%)

As of 06/18/2025 07:09 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bausch Health Cos NYSE:BHC

$6.19 +0.46 (+8.08%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$6.26 +0.06 (+1.00%)

As of 06/18/2025 07:58 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

NewAmsterdam Pharma NASDAQ:NAMS

$18.20 -0.29 (-1.57%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$18.46 +0.26 (+1.43%)

As of 06/18/2025 07:12 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Sana Biotechnology NASDAQ:SANA

$2.76 -0.05 (-1.78%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.82 +0.06 (+1.99%)

As of 06/18/2025 07:59 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time